Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02587286
Other study ID # Gather mHealth 1
Secondary ID
Status Completed
Phase N/A
First received October 22, 2015
Last updated January 20, 2016
Start date March 2015
Est. completion date December 2015

Study information

Verified date January 2016
Source Gather Health India
Contact n/a
Is FDA regulated No
Health authority India : Astha Independent Ethics CommitteeIndia : M.V. Diabetes Research Centre Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to explore the impact of the Gather Health diabetes management platform diabetics' health behaviors and health outcomes and how providers and diabetics interact with the Gather Health platform.


Description:

The overall aim of the study is to estimate the impact of the Gather Health diabetes management platform on HbA1c, glycemic control, patient behavior, and physical and psychosocial measures. Additionally, this study will investigate patient and provider satisfaction with the platform.

Primary Objective:

Estimate the impact of the Gather Health diabetes management platform on HbA1c among diabetics in 3 cities in India.

Secondary Objective:

1. Estimate the impact of the Gather Health diabetes management platform on medication adherence, blood glucose (BG) control, body mass index (BMI), blood pressure (BP), and other behavior and health measures among diabetics in 3 cities in India.

2. Estimate patient and provider's satisfaction with the platform and the perceived usability and time spent on the platform

3. Generate ideas for future changes to the platform to make it more effective and user-friendly


Recruitment information / eligibility

Status Completed
Enrollment 91
Est. completion date December 2015
Est. primary completion date December 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Type 2 diabetes mellitus, diagnosis for > 6 months.

- Age 18-65, participants of either gender- males or females.

- HbA1c between 7.5% and 12.5% within last 6 months (inclusive).

- On stable diabetes therapy for >3 months prior to enrollment.

- Own an Android Smartphone.

- Participant willing to sign and date written Informed Consent Form to participate in the study.

- Willing to comply with the study schedule and procedures including randomization.

Exclusion Criteria:

- Previously used Gather Health

- Currently using an insulin pump or continuous glucose monitor.

- Pregnant or planning to become pregnant in the next 12 months.

- Severe hearing or visual impairment.

- Active substance, alcohol, or drug abuser (sober <1 year).

- Any psychiatric illness including psychosis or schizophrenia that will impair the patient's ability to complete the study or follow study protocol.

- Recent major surgery or planning to have major surgery

- Significant renal, hepatic, or other disease that may impair patient's ability to complete the study or follow study protocol

- Using glucocorticoids

- Patients who have received or are planning to receive an organ transplant

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


Intervention

Other:
Gather app
Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.

Locations

Country Name City State
n/a

Sponsors (4)

Lead Sponsor Collaborator
Gather Health India DHL Innovation Center, India, Diabetes Action Centre, M.V. Hospital for Diabetes

Outcome

Type Measure Description Time frame Safety issue
Other BMI 6 months No
Other Blood pressure 6 months No
Other Waist Circumference 6 Months No
Other Fasting Blood Glucose 6 Months No
Other Lipids 6 Months No
Other Diabetes Self-care activities 6 Months No
Other Self-efficacy Stanford scale 6 Months No
Other Diabetes Knowledge Adaptation of RAND measure 6 Months No
Other Medication Adherence Visual Analog Scale 6 Months No
Other Blood Glucose Testing Adherence Visual Analog Scale 6 Months No
Other Treatment Satisfaction Adapted RAND measure 6 Months No
Other Diabetes Distress PAID-5 6 Months No
Other mHealth intervention satisfaction Investigator generated 6 Months No
Other BMI 3 months No
Other Blood pressure 3 months No
Other Waist Circumference 3 months No
Other Fasting Blood Glucose 3 months No
Other Lipids 3 months No
Other Diabetes Self-care activities 3 months No
Other Self-efficacy Stanford Scale 3 months No
Other Diabetes knowledge Adapted RAND measure 3 months No
Other Med Adherence Visual Analog Scale 3 months No
Other BG Testing Adherence Visual Analog Scale 3 months No
Other Treatment Satisfaction Adapted RAND measure 3 months No
Other Diabetes Distress PAID-5 3 months No
Other mHealth intervention satisfaction Investigator generated 3 months No
Primary Change in HbA1c 6 months No
Secondary Change in HbA1c 3 months No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05666479 - CGM Monitoring in T2DM Patients Undergoing Orthopaedic Replacement Surgery
Completed NCT05647083 - The Effect of Massage on Diabetic Parameters N/A
Active, not recruiting NCT05661799 - Persistence of Physical Activity in People With Type 2 Diabetes Over Time. N/A
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Completed NCT02836704 - Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose) Phase 4
Completed NCT01819129 - Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes Phase 3
Completed NCT04562714 - Impact of Flash Glucose Monitoring in People With Type 2 Diabetes Using Non-Insulin Antihyperglycemic Therapy N/A
Completed NCT02009488 - Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM) Phase 1
Completed NCT05896319 - Hyaluronic Acid Treatment of the Post-extraction Tooth Socket Healing in Subjects With Diabetes Mellitus Type 2 N/A
Recruiting NCT05598203 - Effect of Nutrition Education Groups in the Treatment of Patients With Type 2 Diabetes N/A
Completed NCT05046873 - A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People Phase 1
Completed NCT04030091 - Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus Phase 4
Terminated NCT04090242 - Impact of App Based Diabetes Training Program in Conjunction With the BD Nano Pen Needle in People With T2 Diabetes N/A
Completed NCT03620357 - Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D) N/A
Completed NCT03604224 - A Study to Observe Clinical Effectiveness of Canagliflozin 300 mg Containing Treatment Regimens in Indian Type 2 Diabetes Participants With BMI>25 kg/m^2, in Real World Clinical Setting
Completed NCT01696266 - An International Survey on Hypoglycaemia Among Insulin-treated Patients With Diabetes
Completed NCT03620890 - Detemir Versus NPH for Type 2 Diabetes Mellitus in Pregnancy Phase 4
Withdrawn NCT05473286 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice
Not yet recruiting NCT05029804 - Effect of Walking Exercise Training on Adherence to Disease Management and Metabolic Control in Diabetes N/A
Completed NCT04531631 - Effects of Dorzagliatin on 1st Phase Insulin and Beta-cell Glucose Sensitivity in T2D and Monogenic Diabetes Phase 2